Clinical Trial

U-LABA/ICS Effects on Exercise Performance, Vilanterol

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 10, 2025 (before its estimated July 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist vilanterol + fluticasone furoate
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-09-27.
Trial Details
NCT Number NCT06066606
Lead Sponsor Morten Hostrup, PhD
Conditions Exercise Performance
Enrollment 30 participants
Start Date 2023-10-03
Primary Completion 2026-07-15 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-10